Use of a new hypersensitive assay for the detection of prostate specific antigen in prostate cancer

Yoichi Arai, Hiroyuki Onishi, Kenji Oishi, Hideo Takeuchi, Osamu Yoshida

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


We have developed a new hypersensitive enzyme immunoassay for prostate specific antigen (PSA) based on the (MARKIT-M PA) assay but employing a two-hour incubation of the primary monoclonal antibody. The analytical sensitivity has been determined at 0.2 ng/ml, calculated as the mean + three standard deviations of the zero calibrator. Serum PSA was measured at least one month after radical prostatectomy (nine patients) or cystoprostatectomy (six patients). Based on the PSA levels of these patients, the recommended PSA cut-off level indicative of residual disease after radical prostatectomy was 0.4 ng/ml. Increasing (>0.4 ng/ml) PSA levels preceded recurrence by eight months in a patient who developed bone metastasis after radical prostatectomy. In two patients treated with endocrine therapy, increasing PSA levels also preceded clinical evidence of progression by between eight and nine months. The study suggests that the newly developed sensitive PSA assay allows for the identification of patients with disease progression and the early commencement of adjuvant treatment.

Original languageEnglish
Pages (from-to)110-115
Number of pages6
JournalJapanese journal of clinical oncology
Issue number2
Publication statusPublished - 1993 Apr


  • Prostate cancer
  • Prostate specific antigen
  • Sensitive assay

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research


Dive into the research topics of 'Use of a new hypersensitive assay for the detection of prostate specific antigen in prostate cancer'. Together they form a unique fingerprint.

Cite this